Current Therapeutic Strategies in MASH: Lifestyle and Pharmacologic Interventions
Nov
2026
Description
This session examines pharmacologic (GLP-1 agonists, resmetirom) and lifestyle-based interventions for MASH/MASLD across adult and pediatric populations, including transplant recipients.
Presentations
11:00 AM
- 11:15 AM
Convention Center - Bluebird Ballroom 1A
Semaglutide and Fibrosis Progression in MASLD: A Target Trial Emulation Comparing Semaglutide Versus DPP-4 Inhibitors in a National Cohort
Binu V. John | Abstract Presenter
11:15 AM
- 11:30 AM
Convention Center - Bluebird Ballroom 1A
Buttermilk Supplementation Ameliorates Hepatic Steatosis in Metabolic Dysfunction Associated Steatotic Liver Disease
Sukriti Baweja, PhD | Abstract Presenter
11:30 AM
- 11:45 AM
Convention Center - Bluebird Ballroom 1A
Impact of Multidisciplinary Care on Longitudinal ALT Outcomes in Children With MASLD
Brandon Perumpail, MD | Abstract Presenter
11:45 AM
- 12:00 PM
Convention Center - Bluebird Ballroom 1A
Semaglutide Improves Liver Health in Non‑Obese Participants With MASH: A Post Hoc Analysis From the Phase 3 ESSENCE Trial
Jörn M Schattenberg, MD, | Abstract Presenter
12:00 PM
- 12:15 PM
Convention Center - Bluebird Ballroom 1A
GLP-1 Receptor Agonist Use After Liver Transplantation in MASH or Metabolic-Risk Recipients Is Associated With Improved Survival and Renal Protection: A Three-Center Cohort Study
Zhihao Li, MD | Abstract Presenter
12:15 PM
- 12:30 PM
Convention Center - Bluebird Ballroom 1A
Structured Lifestyle Intervention Based on Cognitive-Behavioral Therapy Principles Reduces Hepatic Steatosis and Improves Metabolic Parameters in Patients with MASLD: Preliminary Results of a Randomized Controlled Study
Vaclav Smid, Assoc.Prof., MD, PhD | Abstract Presenter
